Full Length Research Paper
References
|
Ananth J, Burgoyne KS, Gadasalli R, Aquino S (2001). How do the atypical antipsychotics work? The Journal of Psychiatry and Neuroscience 26:385-394. |
|
|
Arbonnier M (2004). Trees, shrubs and lianas of West Africa Dry Zones. Weikersheim: Margraf Publishers. |
|
|
Ben-Azu BA, Aderibigbe AO, Omogbiya IA, Ajayi AM, Iwalewa EO (2017). Morin pretreatment attenuates schizophrenia-like behaviors in experimental animal models. Drug Research 67:1-9. |
|
|
Brown RE, Corey SC, Mooren AK (1999). Differences in measures of exploration and fear in MHC congenic C578/61 and B6-H-2K mice. Behavior Genetics 26:263-271. |
|
|
Casadesus V, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, Smith MA (2006). Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochimica et Biophysica Acta 1762:447-452. |
|
|
Chatterjee M, Singh S, Kumari R, Verma KA, Palit G (2012). Evaluation of the antipsychotic potential of Panax quinquefolium in ketamine induced experimental psychosis model in mice. Neurochemical Research 37:759-770. |
|
|
Chindo BA, Bulus A, Tijani AY, Gamaniel KS (2012). Ketamine-enhanced immobility in forced swim test: A possible animal model for the negative symptoms of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 38:310-316. |
|
|
Costall B, Naylor RJ, Nohria V (1978). Climbing behaviour induced by apomorphine in mice: a potent model for the detection of neuroleotic activity. The European Journal of Pharmacology 50:39-50. |
|
|
Costall B, Naylor RJ (1974). On catalepsy and catatonia and the predictability of the cataleptic test for neuroleptics activity. Psychopharmacology 34:233-241. |
|
|
Coyle JT (2006). Glutamate and schizophrenia: beyond the dopamine hypothesis. Cellular and Molecular Neurobiology 26:365-384. |
|
|
Davis J, Moylan S, Harvey BH, Maes M, Berk M (2014). Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries. Australian and New Zealand Journal of Psychiatry 48:512-529. |
|
|
De Deurwaerdère P, Di Giovanni G (2017). Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications. Progress in Neurobiology 151:175-236. |
|
|
de Oliveira L, Spiazzi CMDS, Bortolin T, Canever L, Petronilho F, Mina FG, Dal-Pizzol F, Quevedo J, Zugno AI (2009). Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33:1003-1008. |
|
|
Di Giovanni G, Svob-Strac D, Sole M, Unzeta M, Tipton K, Muck-Seler D, Bolea I, Della CL, Nikolac PM, Pivac N, Smolders I, Stasiak A, Fogel A, De Deurwaerdère P (2016). Monoaminergic and histaminergic strategies and treatments in brain diseases. Frontiers in Neuroscience 10:541. |
|
|
Faludi G, Dome P, Lazary J (2011). Origins and perspectives of schizophrenia research. Neuropsychopharmacol Hung 13(4):185-92. |
|
|
Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohd P, Hoschl C (2006). Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. In: Horacek J, ed. CNS drugs (pp. 389-409). Czech Republic: Adis Data Information BV. |
|
|
Kumar A, Yadav M, Parle P, Dhull DK, Dhingra S (2017). Potential drug targets and treatment of schizophrenia. Inflammopharmacology 28:1-6. |
|
|
Lima LB, Vasconcelos CF, Maranhão HM, Leite VR, Ferreira PA, Andrade BA (2009). Acute and subacute toxicity of Schinus terebinthifolius bark extract. The Journal of Ethnopharmacology, 3:468-73. |
|
|
Lorke D (1983). A new approach to practical acute toxicity testing. Archives of Toxicology 53:275-287. |
|
|
Ior LD, Otimenyin SO, Okwori VA, Umar DM, Azila JJ (2017). Ethnobotanical survey of plants used in the management of mental illnesses in some selected local government areas of Plateau State, Nigeria. Journal of Pharmacognosy and Phytotherapy 9:146-156. |
|
|
Jankelowitz SK (2013). Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatric Disease and Treatment 9:1371-1380. |
|
|
Monte AS, de Souza GC, McIntyre RS, Soczynska JK, dos Santos JV, Macêdo DS (2013). Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathway. Journal of Psychopharmacology 27:1032-1043. |
|
|
Pham AT, Malterud KE, Paulsen BS, Diallo D, Wangensteen H (2011). DPPH radical scavenging and xanthine oxidase inhibitory activity of Terminalia macropteral leaves. Natural Product Communications 6:1125-1128. |
|
|
Stahl SM (2007). Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectrums 12:265-268. |
|
|
Sofowora A (2008). Medicinal Plants and Traditional Medicine in Africa (3rd edition). Ibadan: Spectrum Books Ltd |
|
|
Zugno AI, Chipindo HL, Volpato AM, Budni J, Steckert AV, de Oliveira MB, Heylmann AS, da Silveira Rosa F, Mastella GA, Maravai SG, Wessler PG (2014). Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. Neuroscience 259:223-231. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
